benoxaprofen (Oraflex) Report issue

Small molecule Withdrawn
ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
BENOXAPROFEN is an anti-inflammatory drug indicated for the treatment of arthritis. It was marketed under the brand name ORAFLEX® in the US and as OPREN® in Europe by Eli Lilly and Company. In 1982 Eli Lilly voluntarily withdrew BENOXAPROFEN from the market due to postmarketing reports of severe liver toxicity in patients who took it.   NCATS

Chemistry

  • SMILES: CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C3=CC=C(Cl)C=C3
  • InChIKey: MITFXPHMIHQXPI-UHFFFAOYSA-N
  • Mol. Mass: 301.724
  • ALogP: 4.34
  • ChEMBL Molecule:
    benoxaprofen  
More Chemistry

Pharmacology

Alternative names

(1)-2-(4-chlorophenyl)benzoxazole-5-propionic acid | 2-(2-(4-chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid | 2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid | 2-(4-chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid | benoxaprofen | benoxaprofen ammonium | benoxaprofen, ammonium salt | benoxaprofene | benoxaprofen, (-)-isomer | benoxaprofen, (+-)-isomer | benoxaprofen, (+)-isomer | benoxaprofen monosodium | benoxaprofen, monosodium salt | benoxaprofeno | benoxaprofen sodium | benoxaprofenum | compound 90459 | dl-benoxaprofen | lrcl 3794 | oraflex

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Arthritis (approved 1982)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue